Skip to content

Common and Differentiated Representations Between Social Exclusion and Social Separation

Common and Differentiated Representations Between Social Exclusion and Social Separation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05920707
Enrollment
120
Registered
2023-06-27
Start date
2023-04-20
Completion date
2023-10-01
Last updated
2023-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Social exclusion, Social separation, Oxytocin, Arginine Vasopressin, fMRI

Brief summary

Explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of AVP and OXT on these social interaction function.

Detailed description

A large body of research has shown that there are differences in the neural representation between social exclusion and social segregation, but the results are inconsistent, and the exploration of the neural basis is still insufficient. In addition, there are two mainstream theoretical explanations for these differences, namely the construction-level theory and the emotion-based theory, but there is no consistent theoretical model yet. Therefore, further exploration is necessary to confirm the cognitive and neural mechanisms underlying the differences between social exclusion and social segregation, and to attempt to reveal the theoretical explanations for these differences. In this project, the investigators propose to perform behavioral and functional magnetic resonance imaging (fMRI) techniques to examine the shared or separate neural mechanisms of social exclusion and social segregation (exp 1: social exclusion; exp 2: social separation) and investigate the modulatory effects of OXT/AVP on them (PLC/24IU OXT/20IU AVP).

Interventions

DRUGIntranasal Oxytocin

Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.

DRUGIntranasal Arginine Vasopressin

Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.

DRUGIntranasal placebo

Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.

Sponsors

University of Electronic Science and Technology of China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

Randomized placebo-controlled double-blind between-subject design

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy subjects; 2. Without any past or present psychiatric or neurological disorders; 3. Without any current psychotherapeutic medication.

Exclusion criteria

1. With any past or present psychiatric or neurological disorders; 2. With any current psychotherapeutic medication.

Design outcomes

Primary

MeasureTime frameDescription
Neural index: OXT and AVP effects on fMRI based- social exclusion and social separation tasks45 minutes after treatment administrationComparions between OXT and AVP on social exclusion and social separation on brain activity or representations
Behavioral index: behavioral ratings of social exclusion and social separation tasksImmediately after fMRI scanningComparions between social exclusion and social separation in pain ratings

Countries

China

Contacts

Primary ContactKeith M Kendrick, Dr
k.kendrick.uestc@gmail.com+86-28-61830811
Backup ContactWeihua Zhao, Dr
zarazhao@uestc.edu.cn+8618780247797

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026